Another randomized clinical trial designed to evaluate the superiority of recombinant human erythropoietin to PRBC transfusion in treating anemia in patients with cervical cancer was halted prematurely owing to concerns regarding increased thromboembolic events with recombinant human erythropoietin. This evidence concerns the gene EPO and cervical cancer.